Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Practical recommendations on achieving equitability in biomedical research can advance essential efforts to balance research representation. In this Comment, we highlight how to generate interoperable and robust datasets, engage in thoughtful partnerships with researchers across geographies and cultures, and embrace innovative opportunities to push microbiome research beyond the gut and beyond bacteria.
Antibodies targeting tumour necrosis factor have substantially advanced the treatment of paediatric inflammatory bowel disease. Understanding pharmacokinetics and therapeutic drug monitoring has led to increased efficacy and durability of response. Primary non-response is more common in ulcerative colitis than in Crohn’s disease, highlighting the need for alternative biologic agents and oral small molecules.
Genetic predisposition contributes to disease pathophysiology in irritable bowel syndrome (IBS). This Review provides a comprehensive overview of genetic research in IBS and discusses new concepts in IBS genetics.
Here, the authors provide an overview of benign liver tumours (hepatic haemangioma, focal nodular hyperplasia and hepatocellular adenoma), including pathogenesis, diagnosis and management. Insights into how molecular physiology could inform clinical practice are also highlighted.
In this Review, Jess and colleagues describe the prevalence of depression and anxiety in patients with inflammatory bowel disease, the mechanisms underlying the bidirectional association between these diseases and the effect of treatment on their co-occurrence.
Currently, there is no cure for hepatitis B virus (HBV) infection, which can lead to chronic liver disease and liver cancer, and only a few biomarkers are available. This Roadmap provides an overview of HBV serum biomarkers and their challenges.